Summary & Overview
HCPCS Level II J2325: Injection of Nesiritide, 0.1 mg
HCPCS Level II code J2325 designates an injection of nesiritide, billed per 0.1 mg. Nesiritide is an intravenous vasoactive peptide used in acute heart failure management to reduce cardiac preload and afterload and promote diuresis. As a drug-specific HCPCS code, J2325 is used on medical claims to capture the medication unit administered and to facilitate payer adjudication and pricing.
Payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary covers coverage considerations and billing mechanics relevant across commercial and government payers, noting that utilization of drug-specific HCPCS codes affects reimbursement calculations, prior authorization workflows, and inpatient versus outpatient billing distinctions.
Readers will find a concise explanation of the clinical context for nesiritide, the typical sites of service where the injection is administered (acute care and hospital settings), and what the code represents on a claim. The publication also outlines benchmarks and policy-relevant topics that commonly affect J2325, such as unit-based billing, documentation expectations, and payer coverage policies. Data not included in the input (such as specific payer rates, ICD-10 pairings, and associated taxonomies) are noted as unavailable and are not fabricated here.
Billing Code Overview
HCPCS Level II code J2325 represents the medication nesiritide administered by injection, with the billing unit defined as 0.1 mg. This injectable pharmacologic agent is used in acute cardiac care for its vasodilatory and diuretic effects.
Service type: Injection — therapeutic drug administration
Typical site of service: Hospital inpatient, emergency department, or other acute care settings where intravenous or injectable therapies are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult hospitalized with acute decompensated heart failure presenting with dyspnea, volume overload, elevated jugular venous pressure, and signs of low cardiac output. After initial management including diuretics and vasodilators, the treating cardiology team may order an intravenous infusion of nesiritide for short-term hemodynamic support when there is persistent symptomatic congestion or evidence of elevated pulmonary capillary wedge pressure. The medication billed with J2325 is supplied and administered in the inpatient acute care setting or observation unit via an IV infusion pump under physician or advanced practice provider supervision. Clinical workflow includes baseline vital signs, measurement of renal function and electrolytes, initiation per hospital protocol (bolus uncommon; more often continuous infusion), nursing monitoring for hypotension, documentation of indication and dose in the medical record, and reconciliation of the drug charge with the pharmacy dispensing record. Typical clinicians involved include cardiologists, hospitalists, critical care nurses, and pharmacists.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Used when no other modifier applies to the service |